Related Experiment Video
Updated: Jun 22, 2025
11:34
Exploring Sequence Space to Identify Binding Sites for Regulatory RNA-Binding Proteins
Published on: August 9, 2019
6.6K
Therapeutic Applications of Aptamers
George Santarpia1, Eric Carnes1
1College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, USA.
International Journal of Molecular Sciences
|June 27, 2024
Summary
Aptamers, or nucleic acid-based affinity reagents, offer a cost-effective alternative to antibodies for molecular biology and medicine. Despite challenges like in vivo stability, aptamers show therapeutic promise with FDA-approved drugs and ongoing development for new applications.
Area of Science:
- Biochemistry
- Molecular Biology
- Medical Science
Background:
- Affinity reagents, such as antibodies, are essential tools in molecular biology and medicine.
- Antibodies have limitations including complex production and cost.
- Aptamers present a viable alternative with unique advantages.
Purpose of the Study:
- To highlight aptamers as a versatile class of affinity reagents.
- To compare the advantages and disadvantages of aptamers versus antibodies.
- To discuss the therapeutic potential and ongoing development of aptamers.
Main Methods:
- Selection of single-stranded DNA or RNA aptamers for specific target binding.
- In vitro production and modification of nucleic acid aptamers.
- Review of clinical trial data and FDA approvals for aptamer-based therapeutics.
Main Results:
- Aptamers can bind to a diverse range of targets, including those with low antibody affinity.
- Cost-effective, cell-free production methods are available for aptamers.
- Aptamers have demonstrated success in clinical trials and have received FDA approval for therapeutic use.
Conclusions:
- Aptamers offer a promising alternative to antibodies due to their versatile binding capabilities and cost-effective production.
- Ongoing research in aptamer development may lead to novel therapeutics, including antitoxins and improved efficacy through combinatorial approaches.
- Further development is needed to address challenges such as in vivo stability for broader therapeutic applications.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K